NCT06548854View on ClinicalTrials.gov

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Dose Exploration Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Characteristics of STC314 Injection Administered Intravenously in Sepsis Patients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

November 30, 2024

Study Completion Date

February 28, 2025

Conditions

Sepsis

Interventions

DRUG

STC314 Injection/STC314 Injection Placebo

All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.

Trial Locations (1)

210009

Zhongda Hospital Southeast University, Nanjing